Treatment of Lung Cancer in Women.

Marisa Sewell, Daniela Molena

Abstract readReview

In one paragraph

Review in Surgical oncology clinics of North America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Marisa SewellDepartment of Surgery, Thoracic Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

Daniela MolenaDepartment of Surgery, Thoracic Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Electronic address: molenad@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026

$347.4M

NCI NIH HHS P30 CA008748

6 · The paper itself

Abstract

Lung cancer is the leading cause of cancer death in both men and women in the United States. However, around the world, the incidence and mortality rates from lung cancer in men have been decreasing, whereas they have been rising in women. Additionally, there are clinical, pathologic, and survival differences between men and women who have lung cancer. Despite these well-documented differences, women remain significantly underrepresented in both surgical and non-surgical prospective clinical trials.

Indexed as

Lung NeoplasmsFemaleHumansSex FactorsClinical trialsLung cancerNon-small cell lung cancerWomen

Identifiers

PMID41110866

DOI10.1016/j.soc.2025.04.004

PMCPMC13591371

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.